Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
By T. Davis, A. Grillo‐López, C. White, P. Mclaughlin, M. Czuczman, B. Link, D. Maloney, R. Weaver, J. Rosenberg, R. Levy. Journal of Clinical Oncology, 2000
699 citations recorded by the source corpus.
Subfields: Dermatology, Oncology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/c21b537033d1f0b25c0a0eb8927c982d107c3251
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
Citations in the corpus
- Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. (2004, neutral): “Bone marrow infiltration, involved only, % 25 (1-90) 30 (4-90) 16 (5-90)”
- Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance (2003, background): “Furthermore, if CD20 expression alone determined rituximab responsiveness, then one would expect development of CD20-negative relapses after rituximab treatment, and this circumstance has rarely been reported, at least for indolent lymphoma (Davis et al., 2000).”